Blue Water Vaccines to Present at The Universal Influenza Vaccines 2022 Conference in Oxford, United Kingdom
25 August 2022 - 4:00AM
Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the
Company”) a biopharmaceutical company developing transformational
vaccines to address significant global health challenges, today
announced that scientists from its research partner, The University
of Oxford, will present at The Universal Influenza Vaccines 2022
Conference in Oxford, United Kingdom on Monday, September 5th,
2022.
Sunetra Gupta, Ph.D., Professor of Theoretical Epidemiology at
The University of Oxford and current member of the BWV Scientific
Advisory Board, will present BWV’s approach to a universal
influenza vaccine, BWV-101, containing epitopes of limited
variability identified for influenza H1, H3, and influenza B. The
Company is also developing a standalone H1 pre-pandemic vaccine
containing epitopes of limited variability, BWV-102.
“We are honored for Dr. Gupta to present our technology to such
an esteemed group of colleagues in Oxford, where it all began for
Blue Water Vaccines in 2019,” said Joseph Hernandez, Chairman and
Chief Executive Officer of Blue Water Vaccines. “There is an
immense global need for a lasting, efficacious, influenza vaccine
and we look forward to collaborating with all in attendance at such
a dedicated event.”
In July 2019, the Company entered into an exclusive, global
license agreement relating to the use of epitopes of limited
variability for the development and commercialization of influenza
vaccine candidates. In addition, BWV and Oxford entered into a
Sponsored Research Agreement in December 2019, extended in May
2022, to fund research and optimization of epitopes of limited
variability for influenza vaccine candidate development.
BWV’s management will be available during the conference for
one-on-one meetings. Interested parties may request a one-on-one
meeting at investors@bluewatervaccines.com or contact BWV at
(513) 620-4101.
About Blue Water Vaccines
Blue Water Vaccines Inc. is a biopharmaceutical company focused
on developing transformational vaccines to address significant
health challenges globally. Headquartered in Cincinnati, OH, the
company holds the rights to proprietary technology developed at the
University of Oxford, Cincinnati Children's Hospital Medical
Center, and St. Jude Children's Hospital. The company is developing
a universal flu vaccine that will provide protection from all
virulent strains in addition to licensing a novel norovirus (NoV)
S&P nanoparticle versatile virus-like particle (VLP) vaccine
platform from Cincinnati Children’s to develop vaccines for
multiple infectious diseases, including norovirus/rotavirus and
malaria, among others. Additionally, Blue Water Vaccines is
developing a Streptococcus pneumoniae (pneumococcus) vaccine
candidate, designed to specifically prevent the highly infectious
middle ear infections, known as Acute Otitis Media (AOM), in
children. For more information, visit
www.bluewatervaccines.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements may be identified by the use of
forward-looking words such as “anticipate,” “believe,” “forecast,”
“estimate,” “expect,” and “intend,” among others. These
forward-looking statements are based on BWV’s current expectations
and actual results could differ materially. There are a number of
factors that could cause actual events to differ materially from
those indicated by such forward-looking statements. These factors
include, but are not limited to, risks related to the development
of BWV’s vaccine candidates; the failure to obtain FDA clearances
or approvals and noncompliance with FDA regulations; delays and
uncertainties caused by the global COVID-19 pandemic; risks related
to the timing and progress of clinical development of our product
candidates; our need for additional financing; uncertainties of
patent protection and litigation; uncertainties of government or
third party payor reimbursement; limited research and development
efforts and dependence upon third parties; and substantial
competition. As with any vaccine under development, there are
significant risks in the development, regulatory approval and
commercialization of new products. BWV does not undertake an
obligation to update or revise any forward-looking statement.
Investors should read the risk factors set forth in BWV’s Annual
Report on Form 10-K for the fiscal year ended December 31, 2021,
filed with the Securities and Exchange Commission (the “SEC”) on
March 31, 2022, Quarterly Report on Form 10-Q for the quarter ended
June 30, 2022, filed with the SEC on August 15, 2022 and periodic
reports filed with the SEC on or after the date thereof. All of
BWV’s forward-looking statements are expressly qualified by all
such risk factors and other cautionary statements. The information
set forth herein speaks only as of the date thereof.
Media Contact Information:Blue Water Media
RelationsTelephone: (646) 942-5591 Email:
Nic.Johnson@russopartnersllc.com
Investor Contact Information:Blue Water Investor RelationsEmail:
investors@bluewatervaccines.com
Blue Water Biotech (NASDAQ:BWV)
Historical Stock Chart
From Sep 2024 to Oct 2024
Blue Water Biotech (NASDAQ:BWV)
Historical Stock Chart
From Oct 2023 to Oct 2024